This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

HomePrevnar 20®Prevnar 20® Serotypes matterBurden of diseaseIPDCAPPatient profilesPatient
profilesAge 50+: Arlene, Age 51Diabetes: David, Age 46Asthma: Carly, Age 30COPD: William, Age 48Age 65+: Tyrell, Age 67 Risk for All Underlying Medical ConditionsMary, 65: Healthy ≥65; Unknown Vaccination HistoryCDC recommendationsClinical studiesClinical studiesBuilt on PCV13CAPiTAStudy 1 designStudy 1 resultsStudy 1 safetyStudy 6 designStudy 6 resultsStudy 6 safetyAdministrationAccess & supportAccess & supportMedicareCommercial health plansMaterialsVideosEvents
Prescribing InformationIndicationsPatient SiteOrder Prevnar 20®
Study 6Prevnar 20® (Pneumococcal 20-valent Conjugate Vaccine) immunogenicity in previously vaccinated adults1
Safety profile for adults with previous pneumococcal vaccination1
Percentage of participants in Study 6 with solicited adverse reactions within 7-10 days after vaccination in adults age 65 or older with prior pneumococcal vaccination1*†
Scroll left to view table
  PRIOR PPSV23‡ PRIOR PCV13‡ PRIOR PCV13 and PPSV23‡
Local reaction§ Prevnar 20 (n ‖‖=253) % PCV13 (n ‖‖=121) % Prevnar 20 (n ‖‖=245) % PPSV23 (n ‖‖=126) % Prevnar 20
(n ‖‖=125)
%
Pain at injection
site		 50.2 43.0 61.2 56.3 52.8
Swelling (>2.0 cm)¶** 9.9 6.6 9.4 14.3 4.0
Redness (>2.0 cm)¶** 7.9 2.5 8.6 12.7 4.8
Any local reaction†† 53.0 43.8 64.1 57.9 54.4
Scroll left to view table
Scroll left to view table
  PRIOR PPSV23‡ PRIOR PCV13‡ PRIOR PCV13 and PPSV23‡
Systemic ​​reaction§ Prevnar 20 (n ‖=253) % PCV13 (n ‖=121) % Prevnar 20 (n ‖=245) % PPSV23 (n ‖=126) % Prevnar 20
(n ‖=125)
%
Muscle pain‡‡ 32.0 31.4 33.9 46.0 37.6
Fatigue‡‡ 28.9 23.3 31.0 33.3 32.8
Headache‡‡ 17.8 18.2 13.5 21.4 19.2
Joint pain‡‡ 6.7 10.7 11.8 15.9 16.8
Fever (≥38.0 ˚C) 0.8 0.0 0.0 1.6 0.0
Any
systemic reaction§§		 51.8 43.8 50.2 59.5 52.8
Use of antipyretic
or pain medication‖‖‖‖		 15.8 14.9 17.1 19.8 17.6
PCV13=Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]); PPSV23=23-valent pneumococcal polysaccharide vaccine.Study 6 was conducted in the U.S. and in Sweden.Open-label administration of Prevnar 20.Includes participants who previously received either PPSV23 ≥1 to ≤5 years before enrollment, PCV13 ≥6 months before enrollment, or PCV13 followed by PPSV23 ≥1 year before enrollment in the study.Local reactions measured within 10 days after vaccination; systemic reactions measured within 7 days after vaccination.n=number of participants with any e-diary data reported after vaccination. This value is the denominator for the percentage calculations.Includes all participants who reported a reaction as mild, moderate, or severe during Day 1 to Day 10 after vaccination.Diameters were measured in caliper units (0.5 cm) of whole numbers from 1 to 21 or 21+. Measurements were rounded up to the nearest whole number. Intensity of redness and swelling was characterized as: mild is >2.0 to 5.0 cm; moderate is >5.0 to 10.0 cm; severe is >10.0 cm.“Any local reaction” includes all participants who reported any injection site reaction (pain, swelling, or redness) as mild, moderate, or severe during Day 1 to Day 10 after vaccination.Includes all participants who reported a reaction as mild, moderate, or severe during Day 1 to Day 7 after vaccination.”Any systemic reaction” includes all participants who reported any fever ≥38 °C or any other systemic reaction (fatigue, headache, joint pain, or muscle pain) as mild, moderate, or severe during Day 1 to Day 7 after vaccination.Severity was not collected for use of antipyretic or pain medication. The numbers listed reflect “yes” responses (ie, number of reactions reported).Reference:Prevnar 20® (Pneumococcal 20-valent Conjugate Vaccine) Prescribing Information, Wyeth Pharmaceuticals LLC, 2023. Clinical studies
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
Manufactured by Wyeth Pharmaceuticals LLC.

Marketed by Pfizer Inc.

PP-PNR-USA-2559 © 2025 Pfizer Inc.
All rights reserved. January 2025

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-PNR-USA-2559
You are now leaving PfizerPro You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.PP-MCL-USA-0367
INDICATIONS AND SELECT SAFETY INFORMATION
  • Prevnar 20® is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older
  • Prevnar 20® is indicated for active immunization for the prevention of pneumonia caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 18 years of age and older
  • The indication of Prevnar 20® for the prevention of pneumonia caused by S. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F in individuals 18 years of age and older is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) assay. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial
  • Prevnar 13® is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 18 years of age and older
Prevnar 13® Limitations of Use: Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine

SELECT SAFETY INFORMATION
 
  • Do not administer Prevnar 20® or Prevnar 13® to individuals with severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 20® or Prevnar 13® or to diphtheria toxoid
  • Safety and immunogenicity data on Prevnar 20® are not available for individuals in immunocompromised groups and vaccination should be considered on an individual basis. Based on experience with pneumococcal vaccines, individuals with altered immunocompetence may have reduced immune responses to Prevnar 20®
IMPORTANT SAFETY INFORMATION
  • Do not administer Prevnar 20® or Prevnar 13® to individuals with severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 20® or Prevnar 13® or to diphtheria toxoid
  • Safety and immunogenicity data on Prevnar 20® are not available for individuals in immunocompromised groups and vaccination should be considered on an individual basis. Based on experience with pneumococcal vaccines, individuals with altered immunocompetence may have reduced immune responses to Prevnar 20®
  • Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response to Prevnar 13®
  • For Prevnar 20® in individuals 18 years of age and older, the most commonly reported solicited adverse reactions (>10%) were pain at the injection site, muscle pain, fatigue, headache, and arthralgia. Additionally, injection site swelling was also reported (>10%) in individuals 18 through 59 years of age
  • For Prevnar 13®, in adults 18 years of age and older, the most commonly reported solicited adverse reactions (>5%) were pain, redness, and swelling at the injection site, limitation of arm movement, fatigue, headache, muscle pain, joint pain, decreased appetite, vomiting, fever, chills, and rash
Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please click for Prevnar 20® Full Prescribing Information.

Please click for Prevnar 13® Full Prescribing Information.INDICATIONS
  • Prevnar 20® is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older
  • Prevnar 20® is indicated for active immunization for the prevention of pneumonia caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 18 years of age and older
  • The indication of Prevnar 20® for the prevention of pneumonia caused by S. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F in individuals 18 years of age and older is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) assay. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial
  • Prevnar 13® is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 18 years of age and older
Prevnar 13® Limitations of Use: Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine